Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2016

View Archived Issues

Cobitolimod approved as the international nonproprietary name for Kappaproct

Shanghai Haiyan Pharmaceutical and Yangtze River Pharmaceutical Group report EGFR inhibitors

Atlantic Healthcare initiates phase III trial of alicaforsen to treat IBD pouchitis

FDA grants Novartis' dabrafenib orphan drug designation for malignant glioma

Regeneron's evinacumab granted U.S. orphan status for homozygous familial hypercholesterolemia

siRNA ALN-GO1 given FDA orphan designation for treating primary hyperoxaluria type 1

Shire reports key developments of fourth quarter 2015

Unique mechanism uncovered for high-risk leukemia

Filaggrin inhibits formation of lipid antigens in human skin

PDS Biotechnology and NCI to codevelop novel cancer immunotherapies

FDA issues complete response letter for Remune BLA

Boehringer Ingelheim Pharma patents DPP-I inhibitors

Ferrer discloses antibacterial agents

Roche patent describes TaR-1 ligands

Merck & Co. reports development of CETP inhibitors

Zealand initiates phase II trial of ZP-1848 for short bowel syndrome

Janssen Pharmaceutica divulges mGlu2 receptor modulators

e-Therapeutics reports topline phase IIb results for ETS-6103 in major depressive disorder

JHL Biotech cleared to begin phase I study of rituximab biosimilar JHL-1101

Discovery of a novel RNA delivery system to treat B-cell malignancies

M3 Biotechnology completes series A financing, to move lead compound into clinic

Ennaid Therapeutics to develop therapy for Zika virus

XBiotech enters agreement regarding antibodies for cardiovascular diseases

Achillion Pharmaceuticals begins clinical study of complement factor D inhibitor

FDA awards orphan drug designation to NVX-508 for VOC and ACS in sickle cell disease

Regeneron Pharmaceuticals joins Human Vaccines Project

Incyte to discontinue solid tumor studies of ruxolitinib

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...